HUM vs MET
Humana Inc. and Metlife Inc., side by side — 10 fiscal years reported in USD, drawn from SEC filings.
At a glance
Most recent reported year
| Metric | HUM | MET |
|---|---|---|
| Revenue | $129.7B | $77.1B |
| Net income | $1.2B | $3.4B |
| Gross margin | — | — |
| Net margin | 0.9% | 4.4% |
| Return on equity | 7.0% | 12.1% |
| Diluted EPS | $9.84 | $4.71 |
| Dividend / share | $3.54 | $2.25 |
| Payout ratio | 36.2% | 44.7% |
| Free cash flow | $375.0M | — |
| Equity | $17.7B | $28.4B |
| Net debt / equity | 0.46× | −0.25× |
| Current ratio | 2.00× | — |
| Revenue CAGR 5y | 10.9% | 2.6% |
| Profit CAGR 5y | −18.8% | −9.0% |
HUM bills 1.7× the revenue of MET, and MET keeps more of each dollar of revenue as profit (4.4% against 0.9%).
The stronger figure of the pair is set in bold. That is arithmetic, not a recommendation — this page does not pick a winner.
Revenue by year
10 years side by side
| Fiscal year | HUM | MET |
|---|---|---|
| FY2025 | $129.7B | $77.1B |
| FY2024 | $117.8B | $71.0B |
| FY2023 | $106.4B | $66.9B |
| FY2022 | $92.9B | $68.8B |
| FY2021 | $83.1B | $68.7B |
| FY2020 | $77.2B | $67.8B |
| FY2019 | $64.9B | $69.6B |
| FY2018 | $56.9B | $67.9B |
| FY2017 | $53.8B | $62.3B |
| FY2016 | $54.4B | $60.8B |
Net income by year
Bottom line
| Fiscal year | HUM | MET |
|---|---|---|
| FY2025 | $1.2B | $3.4B |
| FY2024 | $1.2B | $4.4B |
| FY2023 | $2.5B | $1.6B |
| FY2022 | $2.8B | $5.3B |
| FY2021 | $2.9B | $6.9B |
| FY2020 | $3.4B | $5.4B |
| FY2019 | $2.7B | $5.9B |
| FY2018 | $1.7B | $5.1B |
| FY2017 | $2.4B | $4.0B |
| FY2016 | $614.0M | $850.0M |